GT Biopharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference September 26, 2024
GT Biopharma to Host Virtual KOL Event Showcasing its NK Cell Engager Pipeline and Broad Indication Potential on October 10, 2024 September 24, 2024
GT Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update August 14, 2024
GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia June 27, 2024
GT Biopharma, Inc. Announces $3.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules May 21, 2024
Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend GT Biopharma Stockholders Vote “FOR” All Proposed Items at the Upcoming Special Meeting of Stockholders December 6, 2023
